Ticker Details
Novavax, Inc. Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
IPO Date:	December 13, 1995
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.49B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.81 | 3.60%
Avg Daily Range (30 D):	$0.30 | 3.56%
Avg Daily Range (90 D):	$0.20 | 2.50%

Institutional Daily Volume
Avg Daily Volume:	2.74M
Avg Daily Volume (30 D):	5.02M
Avg Daily Volume (90 D):	3.92M

Trade Size
Avg Trade Size (Sh.):	134
Avg Trade Size (Sh.) (30 D):	138
Avg Trade Size (Sh.) (90 D):	143

Institutional Trades
Total Institutional Trades:	8,868
Avg Institutional Trade:	$3.5M
Avg Institutional Trade (30 D):	$1.71M
Avg Institutional Trade (90 D):	$1.94M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.53M
Avg Closing Trade (30 D):	$2.41M
Avg Closing Trade (90 D):	$2.43M
Avg Closing Volume:	229.96K

News

Jan 29, 2026 @ 1:30 PM This Beaten-Down Biotech Is Showing Signs of Life.... Source: Prosper Junior Bakiny

Jan 26, 2026 @ 10:02 PM Stock Market Today, Jan. 20: ImmunityBio Soars Aga... Source: Josh Kohn-Lindquist

Sep 26, 2025 @ 4:08 AM Robert F. Kennedy Jr. Faces Impeachment Push From ... Source: Vishaal Sanjay

Sep 10, 2025 @ 5:21 PM FDA Moves To Publicize Data On Pregnant Women's Co... Source: Vandana Singh

Aug 12, 2025 @ 5:41 PM CDC Shooting Linked To Suspect's COVID-19 Vaccine ... Source: Vandana Singh

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$2.11	$-1.25	$.66
Diluted EPS	$1.78	$-1.25	$.62
Revenue	$1.06B	$70.45M	$239.24M
Gross Profit	$977.05M	$48.95M	$223.92M
Net Income / Loss	$341.75M	$-202.38M	$106.51M
Operating Income / Loss	$307.49M	$-178.02M	$101.07M
Cost of Revenue	$87.6M	$21.5M	$15.33M
Net Cash Flow	$-305.23M	$14.38M	$-9.5M
PE Ratio	5.31

Splits
May 10, 2019	1:20